A Study of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Being Treated With Renin-Angiotensin System Inhibitors - Related Studies

A Study of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Being Treated With Renin-Angiotensin System Inhibitors

This study is ongoing, but not recruiting participants.

Study NCT00421733. Last updated on November 14, 2008. Information provided by Abbott

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Diabetic Nephropathy
		Chronic Kidney Disease Stages 3 & 4

2	Additional conditions recognized in this trial
		Albuminuria
		Diabetic Nephropathies
		Kidney Diseases
		Kidney Failure, Chronic

3	More general conditions related to this trial
		Diabetes Complications
		Diabetes Mellitus
		Endocrine System Diseases
		Kidney Failure
		Proteinuria
		Renal Insufficiency
		Renal Insufficiency, Chronic
		Signs and Symptoms
		Urination Disorders
		Urologic Diseases
		Urological Manifestations

4	Interventions listed in this trial
		Zemplar (paricalcitol ) capsules
		Zemplar (paricalcitol) capsules
		Placebo

5	Additional drug interventions recognized in this trial
		Ergocalciferols

6	More general drug interventions related to this trial
		Bone Density Conservation Agents
		Growth Substances
		Micronutrients
		Pharmacologic Actions
		Physiological Effects of Drugs
		Vitamins

7	Sponsors listed in this trial
		Abbott